Indications
Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.
Composition
- Active substance
- Plerixafor
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mozobil
- Active substance
- Plerixafor
- ATC code
- L03AX16
- Therapeutic area
- Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Lymphoma
- Marketing authorisation holder